세계의 흡입 캡슐 시장 규모, 점유율, 동향 분석 : 유형별, 용도별, 지역별 전망 및 예측(2024-2031년)

The Global Inhalation Capsules Market size is expected to reach $1.4 billion by 2031, rising at a market growth of 5.9% CAGR during the forecast period.

Several factors contribute to the high prevalence of asthma in the U.S., including air pollution, allergens, tobacco smoke, and obesity. Urban areas, particularly in the Northeast and Midwest, have higher asthma rates due to higher air pollution and allergens. Consequently, the North America region generated USD 312.7 million revenue of the market in 2023. Moreover, the region has high healthcare spending, allowing patients better access to advanced treatment options, including inhalation capsules.

Technological advancements have resulted in the development of inhalation devices that are easier to use and more intuitive for patients. Features such as one-click mechanisms, ergonomic designs, and simplified instructions make inhalation devices more user-friendly, improving patient adherence and satisfaction. Advanced inhalation devices incorporate mechanisms to ensure precise and consistent medication dosing. Therefore, as these technological advancements evolve, the market is expected to expand further.

Additionally, as healthcare infrastructure improves and access to medical services increases, a growing demand for effective and convenient treatment options for respiratory diseases drives the demand for inhalation capsules. For example, in countries like China and India, where the healthcare industry is rapidly expanding, there is a significant increase in the prevalence of respiratory diseases due to factors such as air pollution and smoking. Hence, the substantial expansion of the healthcare industry globally has created a conducive environment for the growth of the market.

However, Inhalation capsules deliver medication directly to the lungs, but some amount of the drug may enter the bloodstream and cause systemic side effects. These side effects can include cardiovascular effects, changes in blood pressure, or alterations in metabolic parameters. Particularly with prolonged use or high doses, patients and medical professionals may be concerned about the potential for systemic adverse effects associated with inhalation therapies. Hence, these factors may hamper the market's growth.

Furthermore, the COVID-19 pandemic reshaping demand dynamics, supply chains, and healthcare delivery methods. With the heightened focus on respiratory health during the pandemic, there was an increased demand for medications delivered via inhalation capsules, driven by patients seeking to manage respiratory conditions such as asthma and COPD. Thus, the pandemic had an overall positive impact on the market.

By Type Analysis

Based on type, the market is characterized by gelatin capsules and hypromellose capsules. In 2023, the hypromellose capsules segment recorded a 38.2% revenue share in the market. Hypromellose capsules, also known as hydroxypropyl methylcellulose (HPMC) capsules, are gaining within the market. HPMC capsules offer several key benefits that make them well-suited for inhalation therapy. This versatility enables pharmaceutical companies to develop inhalation capsules containing various active pharmaceutical ingredients, catering to the specific needs of patients with different respiratory conditions.

By Application Analysis

On the basis of application, the market is classified into asthma treatment, COPD management, and others. The asthma treatment segment procured 48.5% revenue share in the market in 2023. Asthma treatment within the market encompasses a wide range of medications and delivery devices tailored to manage the symptoms and underlying inflammation associated with this chronic respiratory condition. Inhalation therapy is considered the cornerstone of asthma management because it delivers medications directly to the lungs, resulting in rapid onset of action, targeted treatment, and reduced systemic side effects.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Europe region held a 29.3% revenue share in the market in 2023. Europe is a leader in healthcare technology, leading to the development of advanced inhalation devices and formulations that drive market growth. Patients and healthcare professionals alike are well-informed regarding the advantages of inhalation therapy, which is propelling market expansion. Moreover, Europe has a favorable regulatory environment for developing and commercializing inhalation capsules, encouraging market growth.

Recent Strategies Deployed in the Market

• Mar-2024: AstraZeneca Pharma India Limited, a subsidiary of AstraZeneca PLC, signed an agreement with Mankind Pharma Limited, a pharmaceutical company. Under this agreement, Mankind Pharma will exclusively distribute budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India.
• Dec-2023: AstraZeneca PLC got approval for its inhalation aerosol from the Central Drugs Standard Control Organisation (CDSCO). The inhalation aerosol consists of a triple combination of budesonide (160 mcg), glycopyrrolate (9 mcg), and formoterol fumarate (4.8 mcg) and is prescribed for the treatment and maintenance of patients with chronic obstructive pulmonary disease (COPD).
• May-2021: Vectura Group Plc expanded its dry powder inhaler (DPI) development and manufacturing capabilities at its facility in Chippenham, U.K. Through this expansion, the company aims to facilitate integration with capsule inhaler devices, such as Vectura's open inhale close (OIC) device and the lever-operated multi-dose inhaler (LOMI) device utilized in Hikma's generic Advair product.
• Mar-2021: Chiesi USA, Inc., a subsidiary of Chiesi Farmaceutici S.p.A., unveiled its bronchitol (mannitol) inhalation powder. The product is a dry powder-inhaled mucoactive agent that is compact, discrete, and portable and does not necessitate any nebulization, refrigeration, or routine cleaning.
• Nov-2020: Chiesi Farmaceutici S.p.A. came into a partnership with Kaia Health Software GmbH, a digital therapeutics company. Under this partnership, the companies will market the Kaia Health Chronic Obstructive Pulmonary Disease (COPD) Pulmonary Rehabilitation app across Europe. Additionally, the partnership aims to provide patients with a digital therapeutic tool that facilitates COPD treatment outcomes by fostering behaviour change.

List of Key Companies Profiled

• Cipla Limited
• Novartis AG
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Lonza Group Ltd. (Capsugel)
• Chiesi Farmaceutici S.p.A
• Vectura Group Plc (Philip Morris International, Inc.)
• Elpen S.A.
• Healthcaps India Ltd.
• Qualicaps Co., LTD. (Roquette Freres SA)

Global Inhalation Capsules Market Report Segmentation

By Type

• Gelatin Capsules
• Hypromellose Capsules

By Application

• Asthma Treatment
• COPD Management
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1.Market Scope & Methodology

• 1.1Market Definition
• 1.2Objectives
• 1.3Market Scope
• 1.4Segmentation
  • 1.4.1Global Inhalation Capsules Market, by Type
  • 1.4.2Global Inhalation Capsules Market, by Application
  • 1.4.3Global Inhalation Capsules Market, by Geography
• 1.5Methodology for the research

Chapter 2.Market at a Glance

• 2.1Key Highlights

Chapter 3.Market Overview

• 3.1Introduction
  • 3.1.1Overview
    • 3.1.1.1Market Composition and Scenario
• 3.2Key Factors Impacting the Market
  • 3.2.1Market Drivers
  • 3.2.2Market Restraints
  • 3.2.3Market Opportunities
  • 3.2.4Market Challenges
• 3.3Porter's Five Forces Analysis

Chapter 4.Recent Strategies Deployed in Inhalation Capsules Market

Chapter 5.Global Inhalation Capsules Market by Type

• 5.1Global Gelatin Capsules Market by Region
• 5.2Global Hypromellose Capsules Market by Region

Chapter 6.Global Inhalation Capsules Market by Application

• 6.1Global Asthma Treatment Market by Region
• 6.2Global COPD Management Market by Region
• 6.3Global Others Market by Region

Chapter 7.Global Inhalation Capsules Market by Region

• 7.1North America Inhalation Capsules Market
  • 7.1.1North America Inhalation Capsules Market by Type
    • 7.1.1.1North America Gelatin Capsules Market by Region
    • 7.1.1.2North America Hypromellose Capsules Market by Region
  • 7.1.2North America Inhalation Capsules Market by Application
    • 7.1.2.1North America Asthma Treatment Market by Country
    • 7.1.2.2North America COPD Management Market by Country
    • 7.1.2.3North America Others Market by Country
  • 7.1.3North America Inhalation Capsules Market by Country
    • 7.1.3.1US Inhalation Capsules Market
      • 7.1.3.1.1US Inhalation Capsules Market by Type
      • 7.1.3.1.2US Inhalation Capsules Market by Application
    • 7.1.3.2Canada Inhalation Capsules Market
      • 7.1.3.2.1Canada Inhalation Capsules Market by Type
      • 7.1.3.2.2Canada Inhalation Capsules Market by Application
    • 7.1.3.3Mexico Inhalation Capsules Market
      • 7.1.3.3.1Mexico Inhalation Capsules Market by Type
      • 7.1.3.3.2Mexico Inhalation Capsules Market by Application
    • 7.1.3.4Rest of North America Inhalation Capsules Market
      • 7.1.3.4.1Rest of North America Inhalation Capsules Market by Type
      • 7.1.3.4.2Rest of North America Inhalation Capsules Market by Application
• 7.2Europe Inhalation Capsules Market
  • 7.2.1Europe Inhalation Capsules Market by Type
    • 7.2.1.1Europe Gelatin Capsules Market by Country
    • 7.2.1.2Europe Hypromellose Capsules Market by Country
  • 7.2.2Europe Inhalation Capsules Market by Application
    • 7.2.2.1Europe Asthma Treatment Market by Country
    • 7.2.2.2Europe COPD Management Market by Country
    • 7.2.2.3Europe Others Market by Country
  • 7.2.3Europe Inhalation Capsules Market by Country
    • 7.2.3.1Germany Inhalation Capsules Market
      • 7.2.3.1.1Germany Inhalation Capsules Market by Type
      • 7.2.3.1.2Germany Inhalation Capsules Market by Application
    • 7.2.3.2UK Inhalation Capsules Market
      • 7.2.3.2.1UK Inhalation Capsules Market by Type
      • 7.2.3.2.2UK Inhalation Capsules Market by Application
    • 7.2.3.3France Inhalation Capsules Market
      • 7.2.3.3.1France Inhalation Capsules Market by Type
      • 7.2.3.3.2France Inhalation Capsules Market by Application
    • 7.2.3.4Russia Inhalation Capsules Market
      • 7.2.3.4.1Russia Inhalation Capsules Market by Type
      • 7.2.3.4.2Russia Inhalation Capsules Market by Application
    • 7.2.3.5Spain Inhalation Capsules Market
      • 7.2.3.5.1Spain Inhalation Capsules Market by Type
      • 7.2.3.5.2Spain Inhalation Capsules Market by Application
    • 7.2.3.6Italy Inhalation Capsules Market
      • 7.2.3.6.1Italy Inhalation Capsules Market by Type
      • 7.2.3.6.2Italy Inhalation Capsules Market by Application
    • 7.2.3.7Rest of Europe Inhalation Capsules Market
      • 7.2.3.7.1Rest of Europe Inhalation Capsules Market by Type
      • 7.2.3.7.2Rest of Europe Inhalation Capsules Market by Application
• 7.3Asia Pacific Inhalation Capsules Market
  • 7.3.1Asia Pacific Inhalation Capsules Market by Type
    • 7.3.1.1Asia Pacific Gelatin Capsules Market by Country
    • 7.3.1.2Asia Pacific Hypromellose Capsules Market by Country
  • 7.3.2Asia Pacific Inhalation Capsules Market by Application
    • 7.3.2.1Asia Pacific Asthma Treatment Market by Country
    • 7.3.2.2Asia Pacific COPD Management Market by Country
    • 7.3.2.3Asia Pacific Others Market by Country
  • 7.3.3Asia Pacific Inhalation Capsules Market by Country
    • 7.3.3.1China Inhalation Capsules Market
      • 7.3.3.1.1China Inhalation Capsules Market by Type
      • 7.3.3.1.2China Inhalation Capsules Market by Application
    • 7.3.3.2Japan Inhalation Capsules Market
      • 7.3.3.2.1Japan Inhalation Capsules Market by Type
      • 7.3.3.2.2Japan Inhalation Capsules Market by Application
    • 7.3.3.3India Inhalation Capsules Market
      • 7.3.3.3.1India Inhalation Capsules Market by Type
      • 7.3.3.3.2India Inhalation Capsules Market by Application
    • 7.3.3.4South Korea Inhalation Capsules Market
      • 7.3.3.4.1South Korea Inhalation Capsules Market by Type
      • 7.3.3.4.2South Korea Inhalation Capsules Market by Application
    • 7.3.3.5Australia Inhalation Capsules Market
      • 7.3.3.5.1Australia Inhalation Capsules Market by Type
      • 7.3.3.5.2Australia Inhalation Capsules Market by Application
    • 7.3.3.6Malaysia Inhalation Capsules Market
      • 7.3.3.6.1Malaysia Inhalation Capsules Market by Type
      • 7.3.3.6.2Malaysia Inhalation Capsules Market by Application
    • 7.3.3.7Rest of Asia Pacific Inhalation Capsules Market
      • 7.3.3.7.1Rest of Asia Pacific Inhalation Capsules Market by Type
      • 7.3.3.7.2Rest of Asia Pacific Inhalation Capsules Market by Application
• 7.4LAMEA Inhalation Capsules Market
  • 7.4.1LAMEA Inhalation Capsules Market by Type
    • 7.4.1.1LAMEA Gelatin Capsules Market by Country
    • 7.4.1.2LAMEA Hypromellose Capsules Market by Country
  • 7.4.2LAMEA Inhalation Capsules Market by Application
    • 7.4.2.1LAMEA Asthma Treatment Market by Country
    • 7.4.2.2LAMEA COPD Management Market by Country
    • 7.4.2.3LAMEA Others Market by Country
  • 7.4.3LAMEA Inhalation Capsules Market by Country
    • 7.4.3.1Brazil Inhalation Capsules Market
      • 7.4.3.1.1Brazil Inhalation Capsules Market by Type
      • 7.4.3.1.2Brazil Inhalation Capsules Market by Application
    • 7.4.3.2Argentina Inhalation Capsules Market
      • 7.4.3.2.1Argentina Inhalation Capsules Market by Type
      • 7.4.3.2.2Argentina Inhalation Capsules Market by Application
    • 7.4.3.3UAE Inhalation Capsules Market
      • 7.4.3.3.1UAE Inhalation Capsules Market by Type
      • 7.4.3.3.2UAE Inhalation Capsules Market by Application
    • 7.4.3.4Saudi Arabia Inhalation Capsules Market
      • 7.4.3.4.1Saudi Arabia Inhalation Capsules Market by Type
      • 7.4.3.4.2Saudi Arabia Inhalation Capsules Market by Application
    • 7.4.3.5South Africa Inhalation Capsules Market
      • 7.4.3.5.1South Africa Inhalation Capsules Market by Type
      • 7.4.3.5.2South Africa Inhalation Capsules Market by Application
    • 7.4.3.6Nigeria Inhalation Capsules Market
      • 7.4.3.6.1Nigeria Inhalation Capsules Market by Type
      • 7.4.3.6.2Nigeria Inhalation Capsules Market by Application
    • 7.4.3.7Rest of LAMEA Inhalation Capsules Market
      • 7.4.3.7.1Rest of LAMEA Inhalation Capsules Market by Type
      • 7.4.3.7.2Rest of LAMEA Inhalation Capsules Market by Application

Chapter 8.Company Profiles

• 8.1Cipla Limited
  • 8.1.1Company Overview
  • 8.1.2Financial Analysis
  • 8.1.3Segmental and Regional Analysis
  • 8.1.4Research & Development Expense
  • 8.1.5SWOT Analysis
• 8.2Novartis AG
  • 8.2.1Company Overview
  • 8.2.2Financial Analysis
  • 8.2.3Segmental and Regional Analysis
  • 8.2.4Research & Development Expense
  • 8.2.5Recent strategies and developments:
    • 8.2.5.1Trials and Approvals:
  • 8.2.6SWOT Analysis
• 8.3AstraZeneca PLC
  • 8.3.1Company Overview
  • 8.3.2Financial Analysis
  • 8.3.3Regional Analysis
  • 8.3.4Research & Development Expenses
  • 8.3.5Recent strategies and developments:
    • 8.3.5.1Partnerships, Collaborations, and Agreements:
    • 8.3.5.2Trials and Approvals:
  • 8.3.6SWOT Analysis
• 8.4Boehringer Ingelheim International GmbH
  • 8.4.1Company Overview
  • 8.4.2Financial Analysis
  • 8.4.3Regional & Segmental Analysis
  • 8.4.4Research & Development Expenses
  • 8.4.5SWOT Analysis
• 8.5Lonza Group Ltd. (Capsugel)
  • 8.5.1Company Overview
  • 8.5.2Financial Analysis
  • 8.5.3Segmental and Regional Analysis
  • 8.5.4Research & Development Expenses
  • 8.5.5SWOT Analysis
• 8.6Chiesi Farmaceutici S.p.A
  • 8.6.1Company Overview
  • 8.6.2Recent strategies and developments:
    • 8.6.2.1Partnerships, Collaborations, and Agreements:
    • 8.6.2.2Product Launches and Product Expansions:
  • 8.6.3SWOT Analysis
• 8.7Vectura Group plc (Philip Morris International, Inc.)
  • 8.7.1Company Overview
  • 8.7.2Financial Analysis
  • 8.7.3Regional Analysis
  • 8.7.4Research & Development Expenses
  • 8.7.5Recent strategies and developments:
    • 8.7.5.1Partnerships, Collaborations, and Agreements:
    • 8.7.5.2Geographical Expansions:
  • 8.7.6SWOT Analysis
• 8.8Elpen S.A.
  • 8.8.1Company Overview
  • 8.8.2SWOT Analysis
• 8.9Healthcaps India Ltd.
  • 8.9.1Company Overview
  • 8.9.2SWOT Analysis
• 8.10.Qualicaps Co., LTD. (Roquette Freres SA)
  • 8.10.1Company Overview
  • 8.10.2SWOT Analysis

Chapter 9.Winning Imperatives of Inhalation Capsules Market